These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 30343508)

  • 21. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
    Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
    Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.
    Michelakis ED; Tymchak W; Noga M; Webster L; Wu XC; Lien D; Wang SH; Modry D; Archer SL
    Circulation; 2003 Oct; 108(17):2066-9. PubMed ID: 14568893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severe pulmonary arterial hypertension associated with congenital cardiac shunts: evolution under specific treatment.
    Negoi RI; Ghiorghiu I; Filipoiu F; Hostiuc M; Negoi I; Ginghina C
    J Med Life; 2017; 10(2):131-138. PubMed ID: 28616089
    [No Abstract]   [Full Text] [Related]  

  • 24. [Effects of iloprost combined with low dose tadalafil in adult congenital heart disease patients with severe pulmonary arterial hypertension: a single-center, open-label controlled study].
    Zhang C; Huang Y; Huang T; Xia C; Huang X; Zhang G; Yao H; Chen J; Chen J; Wu S; Zhuang J
    Zhonghua Xin Xue Guan Bing Za Zhi; 2014 Jun; 42(6):474-80. PubMed ID: 25164220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Asymmetric Dimethyl-L-Arginine is a Biomarker for Disease Stage and Follow-Up of Pulmonary Hypertension Associated with Congenital Heart Disease.
    Fang ZF; Huang YY; Tang L; Hu XQ; Shen XQ; Tang JJ; Zhou SH
    Pediatr Cardiol; 2015 Jun; 36(5):1062-9. PubMed ID: 25737007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Two-year follow-up of pulmonary arterial hypertension patients treated with sildenafil].
    Franchi SM; Barreto AC; Cícero C; Castro CR; Ribeiro ZV; Lopes AA
    Arq Bras Cardiol; 2010 May; 94(5):671-7. PubMed ID: 20428715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rosuvastatin and vascular dysfunction markers in pulmonary arterial hypertension: a placebo-controlled study.
    Barreto AC; Maeda NY; Soares RP; Cícero C; Lopes AA
    Braz J Med Biol Res; 2008 Aug; 41(8):657-63. PubMed ID: 18797697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hemodynamic impact of pulmonary vasodilators on single ventricle physiology.
    Castaldi B; Bordin G; Padalino M; Cuppini E; Vida V; Milanesi O
    Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29193758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initial experience with tadalafil in pediatric pulmonary arterial hypertension.
    Takatsuki S; Calderbank M; Ivy DD
    Pediatr Cardiol; 2012 Jun; 33(5):683-8. PubMed ID: 22402804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.
    Hassoun PM; Zamanian RT; Damico R; Lechtzin N; Khair R; Kolb TM; Tedford RJ; Hulme OL; Housten T; Pisanello C; Sato T; Pullins EH; Corona-Villalobos CP; Zimmerman SL; Gashouta MA; Minai OA; Torres F; Girgis RE; Chin K; Mathai SC
    Am J Respir Crit Care Med; 2015 Nov; 192(9):1102-10. PubMed ID: 26360334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.
    Lunze K; Gilbert N; Mebus S; Miera O; Fehske W; Uhlemann F; Mühler EG; Ewert P; Lange PE; Berger F; Schulze-Neick I
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():32-8. PubMed ID: 16919008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship.
    Garg N; Sharma MK; Sinha N
    Int J Cardiol; 2007 Sep; 120(3):306-13. PubMed ID: 17174417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
    Vizza CD; Jansa P; Teal S; Dombi T; Zhou D
    BMC Cardiovasc Disord; 2017 Sep; 17(1):239. PubMed ID: 28874133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-Analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database.
    Khouri C; Lepelley M; Roustit M; Montastruc F; Humbert M; Cracowski JL
    Chest; 2018 Jul; 154(1):136-147. PubMed ID: 29275134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension.
    Shapiro S; Traiger G; Hill W; Zhang L; Doran AK
    Cardiovasc Ther; 2013 Oct; 31(5):274-9. PubMed ID: 23841794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.
    Lewis GD; Shah R; Shahzad K; Camuso JM; Pappagianopoulos PP; Hung J; Tawakol A; Gerszten RE; Systrom DM; Bloch KD; Semigran MJ
    Circulation; 2007 Oct; 116(14):1555-62. PubMed ID: 17785618
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding.
    Rai N; Veeroju S; Schymura Y; Janssen W; Wietelmann A; Kojonazarov B; Weissmann N; Stasch JP; Ghofrani HA; Seeger W; Schermuly RT; Novoyatleva T
    Biomed Res Int; 2018; 2018():3293584. PubMed ID: 29511676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patients with pulmonary hypertension related to congenital systemic-to-pulmonary shunts are characterized by inflammation involving endothelial cell activation and platelet-mediated inflammation.
    Brun H; Holmstrøm H; Thaulow E; Damås JK; Yndestad A; Aukrust P; Ueland T
    Congenit Heart Dis; 2009; 4(3):153-9. PubMed ID: 19489942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel therapeutic approaches in pulmonary arterial hypertension: focus on tadalafil.
    Levin YD; White RJ
    Drugs Today (Barc); 2011 Feb; 47(2):145-56. PubMed ID: 21431102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology.
    D'Alto M; Romeo E; Argiento P; Sarubbi B; Santoro G; Grimaldi N; Correra A; Scognamiglio G; Russo MG; Calabrò R
    Int J Cardiol; 2012 Mar; 155(3):378-82. PubMed ID: 21081251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.